# A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

> **NCT00500903** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT00500903
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-15
- **Primary completion:** 2010-08-01
- **Final completion:** 2011-02-23
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500903, "A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00500903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*